Form 4: Twist Bioscience CAO Sells Shares for Tax Obligations

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 1,016 shares of common stock to cover tax withholding obligations related to vested performance stock units.

Summary

• Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (TWST), reported a transaction on October 30, 2025.
• The transaction involved the sale of 1,016 shares of Common Stock at a price of $31.4443 per share.
• This sale was explicitly stated as non-discretionary, executed to cover tax withholding obligations associated with the vesting of Performance Stock Units (PSUs).
• Following this transaction, Robert F. Werner beneficially owns 51,030 shares of Common Stock directly.
• The sale was mandated by the Issuer's equity incentive plans, requiring a 'sell to cover' transaction for tax satisfaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a sale of shares, it's a non-discretionary 'sell to cover' transaction for tax purposes, indicating the vesting of PSUs. This is a routine event and not a signal of lack of confidence in the company.

Positives

• The transaction indicates the vesting of Performance Stock Units (PSUs), suggesting the achievement of performance milestones by the Chief Accounting Officer.

Negatives

• A reduction in insider ownership, although explained as non-discretionary, slightly decreases the direct stake of a key executive in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ('PSUs').
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the non-discretionary nature mitigates concerns about management's confidence.
• Employees (specifically the reporting person): The transaction facilitates the tax obligations arising from vested equity compensation.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary 'sell to cover' transaction by a Chief Accounting Officer to satisfy tax obligations from vested equity. Such transactions are common and do not typically reflect a change in the executive's outlook on the company's fundamentals. Therefore, this filing alone does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate as it does not alter the fundamental investment thesis.

Keywords

Twist Bioscience, TWST, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Performance Stock Units, Robert F. Werner, Chief Accounting Officer